000099736 001__ 99736
000099736 005__ 20230519145508.0
000099736 0247_ $$2doi$$a10.3390/ph14020124
000099736 0248_ $$2sideral$$a123236
000099736 037__ $$aART-2021-123236
000099736 041__ $$aeng
000099736 100__ $$aMazarío, E.
000099736 245__ $$aHighly efficient t2 cobalt ferrite nanoparticles vectorized for internalization in cancer cells
000099736 260__ $$c2021
000099736 5060_ $$aAccess copy available to the general public$$fUnrestricted
000099736 5203_ $$aUniform cobalt ferrite nanoparticles have been synthesized using an electrochemical synthesis method in aqueous media. Their colloidal, magnetic, and relaxometric properties have been analyzed. The novelty of this synthesis relies on the use of iron and cobalt foils as precursors, which assures the reproducibility of the iron and cobalt ratio in the structure. A stable and biocompatible targeting conjugate nanoparticle-folic acid (NP-FA) was developed that was capable of targeting FA receptor positivity in HeLa (human cervical cancer) cancer cells. The biocompatibility of NP-FA was assessed in vitro in HeLa cells using the MTT assay, and morphological analysis of the cytoskeleton was performed. A high level of NP-FA binding to HeLa cells was confirmed through qualitative in vitro targeting studies. A value of 479 Fe+Co mM-1s-1 of transverse relaxivity (r2 ) was obtained in colloidal suspension. In addition, in vitro analysis in HeLa cells also showed an important effect in negative T2 contrast. Therefore, the results show that NP-FA can be a potential biomaterial for use in bio medical trials, especially as a contrast agent in magnetic resonance imaging (MRI).
000099736 536__ $$9info:eu-repo/grantAgreement/ES/MINECO/BIO2017-84246-C2-1-R$$9info:eu-repo/grantAgreement/ES/MINECO-FSE/PGC2018-095642-B-I00
000099736 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000099736 590__ $$a5.215$$b2021
000099736 592__ $$a0.851$$b2021
000099736 594__ $$a4.0$$b2021
000099736 591__ $$aPHARMACOLOGY & PHARMACY$$b69 / 279 = 0.247$$c2021$$dQ1$$eT1
000099736 593__ $$aPharmaceutical Science$$c2021$$dQ1
000099736 591__ $$aCHEMISTRY, MEDICINAL$$b16 / 63 = 0.254$$c2021$$dQ2$$eT1
000099736 593__ $$aDrug Discovery$$c2021$$dQ1
000099736 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000099736 700__ $$aCañete, M.
000099736 700__ $$aHerranz, F.
000099736 700__ $$aSánchez-Marcos, J.
000099736 700__ $$0(orcid)0000-0003-1081-8482$$ade la Fuente, J.M.
000099736 700__ $$aHerrasti, P.
000099736 700__ $$aMenéndez, N.
000099736 773__ $$g14, 2 (2021), 124 [13 pp]$$pPharmaceuticals$$tPharmaceuticals$$x1424-8247
000099736 8564_ $$s409550$$uhttps://zaguan.unizar.es/record/99736/files/texto_completo.pdf$$yVersión publicada
000099736 8564_ $$s2760684$$uhttps://zaguan.unizar.es/record/99736/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000099736 909CO $$ooai:zaguan.unizar.es:99736$$particulos$$pdriver
000099736 951__ $$a2023-05-18-15:07:15
000099736 980__ $$aARTICLE